Licensing Opportunity: Vaccine Against Malaria

 Licensing Opportunity:

Vaccine Against Malaria

Anopheles gambiae mosquito being injected with hemolymph for malaria research study. Credit: NIAID

This protein complex of apical membrane antigen (AMA1) and rhoptry neck protein 2 (RON2) complex is a candidate for an effective malaria vaccine against multiple Plasmodium species. NIAID investigators have demonstrated that interaction between AMA1 and RON2 (or peptide thereof) is essential for malaria parasites to successfully enter human red blood cells. Vaccination with this pre-formed AMA1-RON2 complex produced antibodies that protected against lethal malaria in an in vivo mouse model (P. yoelli) and blocked the entry of human malaria parasites into red blood cells in vitro. 

Read more about this exciting licensing opportunity: https://www.ott.nih.gov/technology/e-066-2013. 

Follow NIAID Tech Transfer on LinkedIn.